Format

Send to

Choose Destination
Respir Med. 2009 Jan;103(1):30-4. doi: 10.1016/j.rmed.2008.09.012. Epub 2008 Nov 1.

Do results of the T-SPOT.TB interferon-gamma release assay change after treatment of tuberculosis?

Author information

1
Division of Pulmonary Diseases, Geneva University Hospital, 1211 Geneva 14, Switzerland.

Abstract

BACKGROUND:

Interferon-gamma (IFN-gamma) production by lymphocytes exposed to antigens specific of Mycobacterium tuberculosis has been shown to correlate with antigen load and disease activity.

AIM OF STUDY:

To determine whether treatment of tuberculosis (TB) led to a decrease and/or a reversion of results of a IFN-gamma release assay (T-SPOT.TB, Oxford Immunotec, UK) and thus if T-SPOT.TB could be used to monitor response to treatment.

METHODS:

Qualitative and quantitative analysis (SFUs: spot-forming units) of T-SPOT.TB in HIV-negative patients with TB, during initial 2 weeks of treatment (T0), at end of treatment (TE) and 6 months later (TE+6).

RESULTS:

Mean SFU (SD) was 75 (58; n=62) at T0, 46 (55; n=55) at TE, and 33 (46; n=41) at TE+6; positive rate was 98%, 93% and 98%, respectively. SFUs (paired samples, n=36) decreased significantly between T0 and TE; 2 reversions occurred between T0 and TE (6%), but none between TE and TE+6. Of 6 patients (17%) with an increase in SFUs between T0 and TE, 5 had a favourable outcome at TE and TE+6.

CONCLUSION:

Decrease in SFUs under treatment suggests a relationship with antigen load; however, persisting high SFUs were not predictive of unfavourable outcome and test reversion was rare.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00595907.

PMID:
18977647
DOI:
10.1016/j.rmed.2008.09.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center